Physician profile
Patrick K Dougherty
NPI 1487985206
$4,807.66
in general payments reported to CMS, 2019-2025
32 companies · $1,141 in 2025
The $1,141 reported for 2025 was more than what 85% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,216 · 2022: $1,012 · 2023: $745 · 2024: $695 · 2025: $1,141.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,580.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,579.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $868.28 | 2021-2024 | Speedicath |
| Endo USA, INC. | $598.94 | 2024-2025 | Xiaflex, Aveed |
| Rochester Medical Corporation | $468.25 | 2021-2022 | |
| Astellas Pharma US INC | $462.36 | 2021-2025 | Xtandi |
| Tolmar, INC. | $310.12 | 2023-2025 | Jatenzo, Eligard |
| Antares Pharma, INC. | $218.10 | 2021-2025 | Xyosted, Nocdurna, Tlando |
| Endo Pharmaceuticals INC. | $195.68 | 2021-2024 | Xiaflex, Aveed |
| Hollister Incorporated | $184.20 | 2021-2023 | Infyna Chic, Vapro Pocket |
| Sumitomo Pharma America, INC. | $178.06 | 2023 | Orgovyx, Gemtesa |
| Karl Storz Endoscopy-America | $171.75 | 2023 | N.A., Hd-View |
| Profound Medical Corp. | $161.46 | 2021-2022 | |
| Baxter Healthcare | $146.05 | 2025 | Floseal |
| Ambu INC. | $121.95 | 2023 | |
| C. R. Bard, INC. & Subsidiaries | $104.02 | 2023 | Bard Urinary Drainage Bag |
| Myovant Sciences INC. | $70.40 | 2021-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bioprotect Medical, INC. | $66.64 | 2025 | Bioprotect Balloon Implant System |
| Edap Technomed INC | $66.00 | 2024 | |
| Tempus Ai, INC | $48.28 | 2024 | |
| Blue Earth Diagnostics | $45.53 | 2021-2025 | Posluma |
| Urovant Sciences INC | $36.40 | 2021-2022 | |
| Boston Scientific Corporation | $33.69 | 2021-2023 | |
| Pfizer INC. | $32.59 | 2021-2022 | |
| Convatec INC. | $26.64 | 2022 | |
| Ferring Pharmaceuticals INC. | $26.26 | 2025 | Adstiladrin |
| Halozyme INC | $24.91 | 2023 | |
| Merck Sharp & Dohme LLC | $23.85 | 2024 | Keytruda |
| 180 Medical, INC. | $22.88 | 2022 | |
| Urogen Pharma, INC. | $21.47 | 2024 | |
| Allergan, INC. | $20.22 | 2022 | |
| Myriad Genetic Laboratories, INC. | $19.59 | 2025 | Prolaris |
| Immunitybio, INC. | $18.90 | 2025 | |
| Biotissue Holdings INC. | $14.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Dougherty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.